Are you an Animas pumper or do you know anyone who is? If so, read on for two important pieces of information that Animas pumpers should know:
1. Last chance to get Animas pump supplies:
Did you know September 30, 2019 is the last day to get Animas pump supplies? Animas, Medtronic, and all other supply companies will no longer be selling supplies after this date. If you need to place your final supply order, call 877-937-7867 before September 30, 2019.
2. There are still options for Animas pumpers:
Animas pumpers who have not begun the process of transitioning should know there are options. We understand this can be a difficult decision and we’re happy to discuss the Medtronic insulin pump options available to you.
- For Animas in-warranty customers, we are offering either a system or a insulin pump via a low or no-cost program* through September 30, 2019.
- For Animas out-of-warranty customers, you can switch to the MiniMed 670G system or MiniMed 630G pump.
Call Medtronic at 855-322-9568 to learn more or visit www.MedtronicDiabetes.com/Animas.
*Restrictions apply. Programs available to qualified customers with a valid prescription. Cost may vary based on warranty status, program eligibility and insurance coverage. Program terms and conditions are subject to change at any time and without notice.
What are former Animas pumpers saying?
Sage, a former Animas pumper, switched to the MiniMed 670G system.
“The MiniMed 670G system gives you much less of a burden. Even something as little as not having to worry at night makes a huge difference, and the pump is working all day and night to help prevent spikes and lows** which is a huge help.”
–Sage, Medtronic Ambassador
**Refers to Auto Mode. Some user interaction required. Individual results may vary. Sage was compensated for spending the day with us and allowing us to film her. Her thoughts and opinions are her own.
Important Safety Information
IMPORTANT SAFTEY INFORMATION: MINIMED™ 670G SYSTEM
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safetyinformation#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library
IMPORTANT SAFETY INFORMATION: MINIMED™ 630G SYSTEM
MINIMED™ 630G SYSTEM WITH SMARTGUARD™ TECHNOLOGY Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
See www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.
, Animas Vibe
, insulin pump
, MiniMed 630g
, minimed 670g
, OneTouch Ping
, type 1 diabetes